Gene Bank Operator to Launch IPO Share Sale Next Week
China’s largest biotech startup BGI Genomics Co. said it will start taking orders over the internet next week for its upcoming initial public offering (IPO), as it becomes the latest in a string of similar companies to list on the nation’s Nasdaq-like ChiNext board for high-growth stocks.
BGI, which won approval for the listing last month, said it will begin accepting online orders for the offering of no more than 40.1 million shares on July 5, with a target of raising 484 million yuan ($71 million), according to its latest filing to the Shenzhen stock exchange from the sale.
The company said it would set a preliminary price range for the offering on Thursday and Friday, and will conduct an online road show on Tuesday before it starts taking orders.
When it filed its IPO prospectus last month, the company said it planned to issue about 40 million shares with a total fundraising target of 1.73 billion yuan, translating to an approximate price of 43.3 yuan per share. The latest filing did not elaborate on where the balance of the funds in that original target would come from beyond the 484 million yuan worth or shares being offered in the latest announcement.
The company, which is establishing China’s first national gene bank, posted average annual revenue growth of 23% between 2014 and 2016, including 29% growth last year when the figure rose to 1.71 billion yuan, according to its prospectus. Its profit rose 28% to 350 million yuan in 2016. Some of its largest clients include state-owned China National Tobacco Corp. and the University of Oxford.
Its early investors include some of the most active and high-profile names in China, such as Sequoia Capital, Softbank and Yunfeng Capital.
The IPO would mark the latest for a group of genetic sequencing concept companies, which have become a focus area for development by Beijing as it tries to nurture emerging high-tech industries. Other ChiNext-listed stocks from the group include Dian Diagnostics, Chinasun Pharmaceutical Machinery, Beilu Pharma, Anke Bio and C&Y Pharmaceutical.
Contact reporter Yang Ge (firstname.lastname@example.org)
Apr 09 05:51 PM
Apr 09 04:54 PM
Apr 09 02:08 PM
Apr 08 07:01 PM
Apr 08 07:00 PM
Apr 08 05:11 PM
Apr 08 01:30 PM
Apr 07 06:52 PM
Apr 07 02:03 PM
Apr 06 06:55 PM
Apr 06 05:03 PM
Apr 06 01:50 PM
Apr 02 06:28 PM
Apr 02 05:42 PM
Apr 02 03:55 PM
- 1Call of Duty Mobile Developer Outplays Games Publisher as Timi Studio Earns More Than Activision Blizzard
- 2Huawei Deactivates AI and Cloud Business Group in Restructuring
- 3China Services Expansion Hits Three-Month High, Caixin PMI Shows
- 4China Signals Willingness to Further Open Up Its Military-Controlled Skies
- 5Cover Story: How a Gigantic Ship Shows the Fragility of Global Trade
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas